Lymphoma

The addition of copanlisib to rituximab extended PFS among patients with relapsed follicular lymphoma or marginal zone lymphoma, according to a subset analysis of the randomized phase 3 CHRONOS-3 trial.

Patients with cancer who contracted COVID-19 had high risk for inpatient hospital admission and death, according to study results presented during the virtual ASCO Annual Meeting.

The FDA granted priority review designation to zanubrutinib for treatment of certain adults with marginal zone lymphoma, according to the agent’s manufacturer.

The replacement of vincristine with brentuximab vedotin in standard front-line treatment appeared safe and effective among children and adolescents with high-risk classical Hodgkin lymphoma, according to phase 2 study results.

The FDA cleared an investigational new drug application for MB-106, a chimeric antigen receptor T-cell therapy designed to treat patients with relapsed or refractory, CD20-positive B-cell malignancies.

The additional distance that Americans must travel to receive chimeric antigen receptor T-cell therapy compared with other cancer treatments varies greatly by region, according to a study by health care consulting firm Avalere Health.

The FDA cleared an investigational new drug application for NKX019, a chimeric antigen receptor-natural killer cell therapy for patients with relapsed or refractory B-cell malignancies, according to the agent’s manufacturer.

The development of chimeric antigen receptor T cells has provided hope for patients with hematologic malignancies, but their commercial use has been limited to an option of last resort.

The medical research community’s swift response to the COVID-19 pandemic has led to the development of multiple vaccines within less than a year and the full vaccination of 94 million Americans against the novel coronavirus.

The Leukemia & Lymphoma Society’s therapy acceleration program announced five investments intended to hasten development of immunotherapies to treat blood cancers.